A Multicenter Phase II Clinical Trial Evaluating the Efficacy and Safety of QLS12010 Capsules in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa
Latest Information Update: 27 Feb 2026
At a glance
- Drugs QLS 12010 (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 27 Feb 2026 New trial record